Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 73

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 73
---
 four core areas:

| ● | Early Detection. Multi-cancer                                                                                                                
 early detection (“MCED”) blood tests are advanced diagnostic tools that analyze cell-derived molecules present in the                        
 bloodstream. These tests specifically look for genetic mutations, epigenetic alterations, cell-free DNA fragment patterns, gene expressions, 
 proteomic patterns or other genetic alterations of these tumor-derived molecules, which can indicate the presence of cancer cells.           
 By examining the molecules shed from cancer cells, MCED tests aim to detect cancer at an early stage employing a non-invasive blood          
 test.                                                                                                                                        |

<div align='center'>39</div>

| ● | Recurrence of cancer.                                                                                                                 
 A recurrence refers to the return of cancer after a period of remission. A cancer recurrence happens because, in spite of the efforts 
 to eradicate the cancer, some cells may remain, which grow and eventually cause symptoms. In rare instances, a patient may develop    
 a new cancer that’s completely unrelated to the originally diagnosed cancer, which is referred to as a second primary cancer.         |
| ● | Response to treatment.                                                                                                                
 Most cancer treatments that are currently available are only effective in 30-40% of the cases. In life threatening cases these        
 patients only have one option and therefore reduce their chances of survival significantly. Particularly, in patients with cancer,    
 it is critical to be the ‘first time right’. RenCube aims to develop a new array of diagnostic products that can accurately           
 identify patients that are going to respond or fail to a certain drug thereby facilitating personalized treatment.                    |
| ● | Treatment monitoring.                                                                                                                 
 Current imaging modalities, while valuable, may not be sensitive enough to capture subtle changes in tumor size to guide treatment    
 adjustments effectively. Furthermore, the cost and availability of these imaging techniques can pose barriers to frequent monitoring, 
 potentially delaying necessary interventions. RenCube aims to develop non-invasive liquid biopsy tests that will provide real-time    
 accurate feedback on tumor response thereby empowering clinicians to personalize treatment plans, optimize outcomes, and minimize     
 unnecessary interventions, ultimately improving patient care and quality of life.                                                     |

Renovaro Cube’s Technology and Techniques

RenCube’s AI technology aims
to address three critical facets of medical needs within the domain of cancer diagnosis:

| ● | type-specific cancer detection; |
| ● | pan-cancer detection; and       |
| ● | personalized treatment          |

The foundational architecture of
RenCube’s AI technology will be engineered to facilitate comprehensive pan-cancer analysis through its extensive record of informative
bi